BioRestorative Therapies Announces Key Milestone of Dosing Completion in Safety Cohort of Phase 2 Trial Targeting Chronic Lumbar Disc Disease
June 12, 2023 07:00 ET
|
BioRestorative Therapies, Inc
--Clinical data expected to be reviewed by independent data safety monitoring board (DSMB) as to initial safety dosing profile of BRTX-100-- MELVILLE, N.Y., June 12, 2023 (GLOBE NEWSWIRE) --...
BioRestorative Therapies, Inc. to attend the Jefferies 2023 Healthcare Conference
June 01, 2023 09:15 ET
|
BioRestorative Therapies, Inc
MELVILLE, NY., June 01, 2023 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies,...
BioRestorative Therapies to Seek FDA Approval to Expand the Clinical Application of BRTX-100
March 13, 2023 07:00 ET
|
BioRestorative Therapies, Inc
Bruder Consulting & Venture Group engaged to expand BRTX-100 clinical indication pipeline MELVILLE, N.Y., March 13, 2023 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”,...
BioRestorative Therapies CEO Lance Alstodt to be Interviewed on Famela and Friends Talk Radio Show
October 20, 2022 09:30 ET
|
BioRestorative Therapies, Inc
MELVILLE, N.Y., Oct. 20, 2022 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies,...
BioRestorative Therapies Announces First Patient Enrolled for the Company’s Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease (cLDD)
June 30, 2022 07:30 ET
|
BioRestorative Therapies, Inc
First Patient Enrollment Milestone Completed MELVILLE, NY., June 30, 2022 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (NASDAQ: BRTX), a clinical stage...
BioRestorative Therapies Announces Clinical Trial Contract with Second Site for the Company’s Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease (cLDD)
June 22, 2022 07:30 ET
|
BioRestorative Therapies, Inc
MELVILLE, NY., June 22, 2022 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies,...
BioRestorative Therapies Announces Clinical Site Initiation for the Company’s Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease (cLDD)
June 13, 2022 07:00 ET
|
BioRestorative Therapies, Inc
-- First Site Will Enroll First Patient in the Clinical Study-- MELVILLE, NY., June 13, 2022 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (NASDAQ:...
BioRestorative Therapies Announces Selection of 10 Clinical Sites for its Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease
April 18, 2022 08:00 ET
|
BioRestorative Therapies, Inc
MELVILLE, N.Y.,, April 18, 2022 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies,...
BioRestorative Therapies Announces cGMP Cell Manufacturing Facility Certification
April 04, 2022 08:00 ET
|
BioRestorative Therapies, Inc
Certification Gives BioRestorative Therapies Clinical Grade Manufacturing Capabilities MELVILLE, N.Y., April 04, 2022 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company” or...
BioRestorative Therapies Announces Notice of Allowance for New Patent Application in Japan and Expansion of ThermoStem® IP Portfolio
February 02, 2022 08:00 ET
|
BioRestorative Therapies, Inc
Notice of Allowance Grants Protection for Generating Implantable Three-Dimensional Scaffolds MELVILLE, N.Y., Feb. 02, 2022 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company” or...